Cargando…
An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech, New York, NY, USA), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms o...
Autores principales: | Khor, Seik-Soon, Omae, Yosuke, Takeuchi, Junko S., Fukunaga, Ami, Yamamoto, Shohei, Tanaka, Akihito, Matsuda, Kouki, Kimura, Moto, Maeda, Kenji, Ueda, Gohzoh, Mizoue, Tetsuya, Ujiie, Mugen, Mitsuya, Hiroaki, Ohmagari, Norio, Sugiura, Wataru, Tokunaga, Katsushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029840/ https://www.ncbi.nlm.nih.gov/pubmed/35455312 http://dx.doi.org/10.3390/vaccines10040563 |
Ejemplares similares
-
SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study
por: Takeuchi, Junko S., et al.
Publicado: (2022) -
Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022) -
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023) -
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
por: Yamamoto, Shohei, et al.
Publicado: (2023) -
Antibody responses and correlates after two and three doses of BNT162b2 COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)